Repligen Corporation (RGEN) Presents at Leerink Global Healthcare Conference 2026 Transcript

Question-and-Answer SessionPuneet SoudaLeerink Partners LLC, Research Division Yes. Okay. Excellent. So maybe always exciting to talk about Repligen, a number of things you have ongoing for you in the markets, strong clinical stage presence that you have and in commercial as well. So maybe -- but let me kick off on the 2026 guide. You framed it as 9% to 13% organic growth rate. And then you pointed out the 500 bps outperformance framework relative to the bioprocessing end market, offset by 200 bps of headwi ...